Experienced in Developmental Reading Disorder

Benedikt H. Schoser

Munich, BY, DE 
Experienced in Developmental Reading Disorder
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Benedikt Schoser practices in Munich, Germany. Mr. Schoser is rated as an Experienced expert by MediFind in the treatment of Developmental Reading Disorder. His top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, Pompe Disease, and Thymectomy.

His clinical research consists of co-authoring 306 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Developmental Reading Disorder.

Gender
Male

Locations

Munich, BY, Germany
Other Locations
Planegg, BY 82152, Germany
Maximilian, BY 80336, Germany
Hamburg, HH, Germany
Baur, NW, Germany
Aachen, NW 80336, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

305 Total Publications

Ecosystem Requirements for E-Health and Digital Monitoring in Neuromuscular Disorders.
Ecosystem Requirements for E-Health and Digital Monitoring in Neuromuscular Disorders.
Journal: Journal of neuromuscular diseases
Published: December 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schoser's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 17 Advanced Conditions
View All 49 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile